On 3 June 2026 the European Medicines Agency (EMA) announced that its Emergency Task Force (ETF) is working with the African Medicines Agency (AMA) and national regulatory authorities in the Democratic Republic of the Congo and Uganda. The collaboration focuses on designing clinical trials and evaluating medical countermeasures for an outbreak of Bundibugyo Ebola virus that the World Health Organization declared a Public Health Emergency of International Concern on 17 May. No authorised vaccines or treatments exist for this strain, so EMA has identified three vaccine candidates—an rVSV‑based, a ChAdOx1 adenovirus platform, and an mRNA vaccine—and three treatment candidates—MBP‑134, remdesivir, and maftivimab—plus the antiviral obeldesivir for post‑exposure prophylaxis. Discussions aim to establish regulatory criteria for rapid, scientifically rigorous trials from early to pivotal stages.
© European Medicines Agency (1995‑).
Summary adapted from EMA materials available at https://www.ema.europa.eu
Made by AI. If you spot anything of concern write us at contact@cybach.com. We’ll promptly correct irregularities.